Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic.
It is just over a quarter of a century since the original identification and characterization of glycogen synthase kinase-3 (GSK-3), a major protein kinase that is involved in the regulation of glucose metabolism. GSK-3 modulates the function of a diverse series of proteins, as well as being associated with a wide variety of human disorders, including neurodegenerative diseases, stroke, bipolar disorder, diabetes and cancer. Not surprisingly, GSK-3 has attracted significant attention as a therapeutic target and as a means to understand the molecular basis of these disorders. Small-molecule GSK-3 inhibitors have now started to reach clinical development for the treatment of various disorders.
Medina
Miguel
M
Neuropharma SA, Avenida de la Industria 52, 28760 Tres Cantos, Madrid, Spain. mmedina@neuropharma.es
Castro
Ana
A
D000818:Animals; D001688:Biological Products / Q000627:therapeutic use; D015195:Drug Design; D038362:Glycogen Synthase Kinase 3 / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D015394:Molecular Structure; D011487:Protein Conformation; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
D001688:Biological Products; D047428:Protein Kinase Inhibitors; D038362:Glycogen Synthase Kinase 3